Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Change in Taxes Change in Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Palvella Therapeutics (PVLA) Amortization of Deferred Charges (2020)

Palvella Therapeutics has reported Amortization of Deferred Charges over the past 2 years, most recently at $199000.0 for Q1 2020.

Quarterly Amortization of Deferred Charges changed N/A to $199000.0 in Q1 2020 from the year-ago period, while the trailing twelve-month figure was $746202.0 through Mar 2020, up 18.55% year-over-year, with the annual reading at $408000.0 for FY2019, N/A changed from the prior year.
Amortization of Deferred Charges was $199000.0 for Q1 2020 at Palvella Therapeutics, down from $365251.0 in the prior quarter.
Over five years, Amortization of Deferred Charges peaked at $199000.0 in Q1 2020 and troughed at $199000.0 in Q1 2020.